New hope for lung cancer: experimental drug ANS02 enters human trials
NCT ID NCT07538804
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a new drug called ANS02 in people with advanced non-small cell lung cancer that has a specific genetic change (EGFR mutation). The trial has two phases: first, finding a safe dose, then checking if the drug shrinks tumors. About 294 participants will take ANS02 alone, and researchers will monitor side effects and how the drug moves through the body.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ANS02 (a drug being tested for advanced lung cancer)
What this could lead to
If successful, this could point toward a new treatment option for people with EGFR-mutated non-small cell lung cancer that hasn't responded to other therapies.
What could go wrong
This is an early first-in-human trial, so safety and effectiveness are not yet known. Many experimental drugs fail in early testing, and side effects could be significant.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL-CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Research Site
RECRUITINGFairfax, Virginia, 22031, United States
-
Research Site
NOT_YET_RECRUITINGGuangzhou, Guangdong, China
-
Research Site
NOT_YET_RECRUITINGHarbin, Heilongjiang, China
-
Research Site
NOT_YET_RECRUITINGZhengzhou, Henan, China